Cause of thromboses ?: AstraZeneca shares just about positive: EMA sees risk as low – British authority informs about examination of thromboses | message
Shares in this article
The press conference is to be broadcast live on television.
The background is “very rare and specific types of blood clots with a low number of platelets after vaccination with AstraZeneca,” as the head of the Medicines and Healthcare products Regulatory Agency (MHRA), June Raine, announced on Tuesday. According to a media report, the agency is considering no longer recommending the vaccine for those under 30.
In Germany, the federal and state health ministers had decided, because of the cases of thrombosis that mainly occurred in young women, to generally only administer the preparation to people aged 60 and over. For younger people, vaccination is only possible after they have been informed about the risks at their own risk.
EMA: No restriction on AstraZeneca vaccine – risks low
The European Medicines Agency (EMA) continues to give the green light for the manufacturer’s corona vaccine. Despite very rare cases of blood clots in cerebral veins, the EMA continues to recommend the use of the vaccine without restriction. “The benefits of the active ingredient in combating Covid-19 are significantly higher than the risks,” said EMA boss Emer Cooke on Wednesday in Amsterdam.
The experts found a connection between vaccine and thrombosis with a very low number of blood platelets. However, this occurs very rarely. The authority thus continues to adhere to its assessment of the preparation. Experts had previously examined reports of thrombosis after vaccination in detail. These analyzes would continue, as the EMA announced.
It is unclear what consequences the EMA decision will now have for the vaccinations. Several EU countries, including Germany, had previously restricted the use of the vaccine to people aged 60 and over. The reason for this were rare cases of blood clots (thrombosis) in cerebral veins after an AstraZeneca vaccination. There were 31 suspected cases in Germany.
As a result, the EMA set up a group of experts in March. She had initially found no connection with the vaccination. But the investigation had continued. The experts suspect that it is a very rare immune reaction. Most of the cases were reported to have occurred about two weeks after the vaccination. The experts had not found any special risk factors such as age or gender.
The EMA advised vaccinated people to watch out for the remote possibility of the very rare blood clots. If symptoms occur, they should seek medical advice immediately, it said. The vaccine with the market name Vaxzevria received conditional marketing authorization for the EU at the end of January. Thereafter, the British-Swedish manufacturer is still obliged to forward all data on possible side effects.
AstraZeneca shares temporarily gain 0.12 percent to 71.38 British pounds in London.
/ cmy / DP / fba
More news about AstraZeneca PLC
Image sources: Oli Scarff / Getty Images